Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227111 | 1.00 | RBP4 (1.00) | RBP4 | |
| SCHEMBL630507 | 0.88 | RBP4 (0.78) | RBP4 | |
| SCHEMBL766250 | 0.85 | RBP4 (0.74) | RBP4 | |
| SCHEMBL633153 | 0.85 | RBP4 (0.74) | RBP4 | |
| SCHEMBL27873708 | 0.84 | RBP4 (0.80) | RBP4 | |
| SCHEMBL766147 | 0.84 | RBP4 (0.72) | RBP4 | |
| SCHEMBL18255868 | 0.83 | RBP4 (0.71) | RBP4 | |
| SCHEMBL766188 | 0.83 | RBP4 (0.71) | RBP4 | |
| SCHEMBL630631 | 0.83 | RBP4 (0.71) | RBP4 | |
| SCHEMBL766160 | 0.83 | RBP4 (0.71) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO INC (US) | 2025-07-31 | — | — | US | claimed |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC | 2024-07-25 | — | — | US | claimed |
| EP-4340701-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | Belite Bio, LLC (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117440774-A | Biomarkers of age-related macular degeneration | 倍亮生物有限责任公司 | 2024-01-23 | — | — | CN | claimed |
| WO-2022246238-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC (US) | 2022-11-24 | — | — | WO | claimed |
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | claimed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | claimed |
| EP-2419413-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | claimed |
| WO-2010119992-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | WO | claimed |
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC | 2024-07-25 | — | — | US | disclosed |
| EP-4340701-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | Belite Bio, LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117440774-A | Biomarkers of age-related macular degeneration | 倍亮生物有限责任公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023200766-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO, INC (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-102459209-A | Derivatives of N-acyl-N' -phenylpiperazines for the prevention or treatment of diabetes (etc.) | TAKEDA PHARMACEUTICAL | 2012-05-16 | — | — | CN | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2419413-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010119992-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | RBP4 1/4885 |
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | PDE6C, SERPINA6, PDE6H | RBP4 11/4885 |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | AGER, RBP4, RBP1 | RBP4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.